Catalyst Event
Biogen Inc (BIIB) · Other
From Akros U.S. Large Cap 500 Index (AUL500)
6/1/2026, 12:00:00 AM
Announced with partner UCB on 2026-06-01 that full results from the Phase 3 PHOENYCS GO trial of dapirolizumab pegol were published in The Lancet. A Low importance is estimated as journal publications usually have a limited impact on stock price, estimated.
Korean Translation
2026년 6월 1일, 협력사 UCB와 함께 전신성 홍반성 루푸스 치료제 다피롤리주맙 페골의 3상 임상 결과가 '더 랜싯'에 게재되었음을 발표함. 학술지 게재의 제한적인 시장 영향을 고려하여 중요도를 'Low'로 예상함.
Related Recent Events
ON Semiconductor Corp (ON) · Other
Financial Analyst Day in New York City to provide updates on strategy and long-term financial plans is scheduled. Impact estimated at >=1% as analyst days usually provide incremental updates; the event is scheduled.
9/16/2026, 12:00:00 AM
Walmart Inc (WMT) · Earnings Release
Walmart's Q2 FY2027 earnings release is scheduled.
8/20/2026, 12:00:00 AM
Lumentum Holdings Inc (LITE) · Earnings Release
Lumentum's next earnings release for Q4 2026 is scheduled for August 11, 2026; high importance as a primary volatility driver scheduled.
8/11/2026, 12:00:00 AM
Conocophillips (COP) · Earnings Release
As quarterly results typically drive price movements exceeding 10% for major energy producers, the Q2 2026 earnings release on 2026-08-06 is scheduled.
8/6/2026, 12:00:00 AM
Rocket Lab Corp (RKLB) · Earnings Release
Second Quarter 2026 financial results and conference call are scheduled for 2026-08-06 scheduled.
8/6/2026, 12:00:00 AM
Kratos Defense & Security Solutions Inc (KTOS) · Earnings Release
Kratos is expected to announce its Q2 2026 earnings on 2026-08-06, with analysts forecasting an EPS of approximately $0.14. This event is estimated to have a ≥5% price impact and is scheduled.
8/6/2026, 12:00:00 AM